Premier Alternatives

Tubulis

Drug Discovery · Planegg-Martinsried, Germany · Founded 2012 · Privately Held (backing)

Developer of chemotherapeutic drugs designed to fight against cancer and chronic diseases. Tubulis is based in Planegg-Martinsried, Germany and was founded in 2012. It was valued at $5.8 billion at a merger or acquisition in Apr 2026, the last priced event on record. It has raised $618 million across 1 recorded round; the latest was a $361 million Series C in Oct 2025.

PMV mark · valuation
$5.8B
Oct 2026
Priced at
a merger or acquisition
Apr 2026
Total raised
$618.5M
Last round
Later Stage VC (Series C)
Oct 2025

Tubulis key facts

as of Oct 2026
  • Developer of chemotherapeutic drugs designed to fight against cancer and chronic diseases.
  • Tubulis is valued at approximately $5.8B as of Oct 2026, set at a merger or acquisition, Apr 2026; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $618.5M across 1 recorded rounds; the latest was Later Stage VC (Series C) ($360.7M) in Oct 2025.
  • Notable investors include Fidelity Management & Research Company, High-Tech Gründerfonds, Blackstone, Bayern Kapital, Venrock — 26 tracked in total.
  • Status: Privately Held (backing).
PrivateMarketView mark
MEDIUM confidence
$5.8B

Valued at $5.8B at a merger or acquisition, Apr 2026. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Tubulis with a free account
  • ·The complete investor list: 26 names
  • ·Everyone on the team, board and advisors included
  • ·Watch Tubulis: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Tubulis funding rounds

1 rounds
Oct 2025Later Stage VC (Series C)$360.7M▮
Full funding history →

Tubulis leadership

Tubulis valuation

Tubulis was valued at $5.8 billion at a merger or acquisition in Apr 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Tubulis raised?

Tubulis has raised $618 million in total; 1 of its rounds is on record. The largest on record was a $361 million Series C in Oct 2025.

Tubulis investors

26 investors are on record for Tubulis, including Fidelity Management & Research Company, High-Tech Gründerfonds, Blackstone and Bayern Kapital. By type, the record holds 7 venture capital firms, 2 asset managers and 1 private equity firm. The Series C in Oct 2025 drew 15 investors.

Who runs Tubulis

22 people are listed on the Tubulis team: 7 executives, 7 board members and 8 advisors and observers, including Jonas Helma-Smets (Chief Scientific Officer) and Halley Gilbert (Chief Legal Officer). 21 of them have a verified direct contact on file.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Halda Therapeutics ($3 billion), Encoded Therapeutics ($1.8 billion) and Formation Bio ($1.7 billion).

About Tubulis

Developer of chemotherapeutic drugs designed to fight against cancer and chronic diseases. The company's chemotherapeutic drugs are uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology, enabling doctors to treat cancer patients without any side effects related to chemotherapy.

Industry
Drug Discovery
Sector
Healthcare
HQ
Planegg-Martinsried, Germany
Founded
2012
Employees
107
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.